GLP-1 Observer
Subscribe
Sign in
Home
Archive
About
Latest
Top
To Be Fair: Novo, Lilly, and How to Compare Obesity Drugs
We compare obesity drugs all the time. What makes a comparison fair? Novo vs. Lilly shows how Wegovy stacks up against Zepbound and what Lilly can…
Aug 26
•
Michael Parker, MD
Keeping Muscle and Losing Fat: The Next Race for Obesity Drugs
Lean mass is not the same as muscle, muscle is not strength, and strength is not the same as carrying the groceries.
Aug 7
•
Michael Parker, MD
1
July 2026
AstraZeneca Steps Up, Novo’s Pill Clears Europe
Week Of July 11 – July 17, 2026
Jul 17
•
Michael Parker, MD
1
The GLP-1 Lilly Isn’t Aiming at Obesity
Week Of July 4 – July 10, 2026
Jul 10
•
Michael Parker, MD
1
A Semaglutide Patch and an Amycretin Bet
Week Of June 27 - July 3, 2026
Jul 3
•
Michael Parker, MD
June 2026
China’s Triple Hits Phase 3, Lilly Bridges Medicare
Week Of June 20 – June 26, 2026
Jun 26
•
Michael Parker, MD
1
Structure Takes the Next Step, Novo’s Pill Pulls Ahead
Week Of June 13 - June 19, 2026
Jun 19
•
Michael Parker, MD
ADA’s Big Week, Lilly and AstraZeneca Among the Headlines
Week Of June 6 - June 12, 2026
Jun 12
•
Michael Parker, MD
1
China’s Incretin Wave, ADA on Deck
Week Of May 30 - June 5, 2026
Jun 5
•
Michael Parker, MD
May 2026
Foundayo Coverage and Dual-Agonist Liver Updates
Week Of May 23 - May 29, 2026
May 29
•
Michael Parker, MD
2
Retatrutide’s Results, Wegovy Gears Up For Europe
Week Of May 16 – May 22, 2026
May 22
•
Michael Parker, MD
1
Maintenance Trials and Drug Responders
Week Of May 9 – May 15, 2026
May 15
•
Michael Parker, MD
1
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts
